Vaishali Pharma (VAISHALI) Q4 25/26 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 were approved, with the first-time consolidation of Kesar Pharma Limited as an associate from September 2025.

• Audit reports for both standalone and consolidated results were issued with unmodified opinions, except for uncertainty regarding long-outstanding receivables.

Financial highlights

• Standalone revenue from operations for FY26 was ₹10,877.23 lakh, up from ₹9,902.56 lakh in FY25.

• Standalone net profit for FY26 was ₹403.17 lakh, compared to ₹81.74 lakh in FY25.

• Consolidated revenue for FY26 was ₹10,877.23 lakh, with consolidated net profit at ₹403.17 lakh and share of profit from associate at ₹13.31 lakh.

• Earnings per share (EPS) for FY26 stood at ₹0.31 (standalone) and ₹0.32 (consolidated).

Outlook and guidance

• No explicit forward-looking guidance provided; management notes the first-time consolidation of an associate and ongoing focus on pharmaceutical sales.